<DOC>
	<DOCNO>NCT00003745</DOCNO>
	<brief_summary>Phase II trial study effectiveness topotecan treat child recurrent , relapse , refractory sarcoma . Drugs use chemotherapy use different way stop tumor cell divide stop grow die .</brief_summary>
	<brief_title>Chemotherapy Treating Children With Recurrent Refractory Sarcomas</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate child recurrent refractory brain tumor , sarcoma , neuroblastomas treated topotecan . ( Brain tumor neuroblastoma stratum close accrual effective 07/02/2001 ) II . Assess toxicity regimen large group patient treat currently define maximum tolerate dose . OUTLINE : This multicenter study . Patients receive topotecan IV continuously day 1-21 . Treatment continue least every 4 week absence unacceptable toxicity disease progression . Patients follow every 3 month .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignancy relapse refractory conventional therapy original diagnosis include : Brain tumor Gliomas astrocytomas Medulloblastomas primitive neuroectodermal tumor ( PNET ) CNS ( Brain tumor stratum close accrual effective 07/02/2001 ) Sarcomas Soft tissue sarcoma ( undifferentiated sarcoma , embryonal alveolar rhabdomyosarcoma ( RMS ) , nonRMS soft tissue sarcoma ) Osteosarcoma Ewing 's sarcoma/peripheral PNET tumor Neuroblastoma ( Neuroblastoma stratum close accrual effective 07/02/2001 ) Histology requirement waive brain stem tumor ( Brain tumor stratum close accrual effective 07/02/2001 ) Measurable disease document clinical , radiographic , histologic criterion Lesions previously irradiate field may use assess tumor response evidence subsequent tumor growth field No bone marrow metastases granulocytopenia and/or thrombocytopenia PATIENT CHARACTERISTICS : Age : 30 day 21 year diagnosis Performance status : ECOG 02 Life expectancy : More 2 month Hematopoietic : Absolute neutrophil count least 1,000/mm3 Hemoglobin least 10.0 g/dL ( may receive RBC transfusion ) Platelet count least 100,000/mm3 ( 50,000/mm3 post bone marrow transplantation ) ( transfusion independent ) Hepatic : Bilirubin great 1.5 time normal SGOT SGPT less 2.5 time normal Renal : Creatinine great 1.5 time normal OR Creatinine clearance radioisotope glomerular filtration rate least 70 mL/min Neurologic : No great grade 2 CNS toxicity OR Stable CNS status brain tumor ( Brain tumor stratum close accrual effective 07/02/2001 ) Seizure disorder allow wellcontrolled anticonvulsant Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 3 month since prior bone marrow transplantation recover At least 2 week since prior cytokine recover No concurrent filgrastim ( GCSF ) cytokines No concurrent immunomodulating agent Chemotherapy : At least 2 week since prior chemotherapy ( 4 week nitrosoureas ) recover No prior topotecan camptothecins No concurrent anticancer chemotherapy Endocrine therapy : Concurrent corticosteroid CNS tumor increase intracranial pressure allow ( Brain tumor stratum close accrual effective 07/02/2001 ) Radiotherapy : At least 2 month since prior craniospinal radiotherapy radiotherapy 50 % bone marrow recover Concurrent radiotherapy localize painful lesion allow provide least 1 measurable lesion irradiate Other : Recovered prior therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>April 2003</verification_date>
	<keyword>recurrent childhood rhabdomyosarcoma</keyword>
	<keyword>recurrent osteosarcoma</keyword>
	<keyword>embryonal childhood rhabdomyosarcoma</keyword>
	<keyword>alveolar childhood rhabdomyosarcoma</keyword>
	<keyword>recurrent childhood soft tissue sarcoma</keyword>
	<keyword>extraosseous Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
</DOC>